Communiqués BioArctic AB

Actions

BIOA B

SE0010323311

Recherche biotechnologique et médicale

Temps réel estimé Cboe Europe Autres places de cotation 14:18:41 12/05/2026			Varia. 5j.	Varia. 1 janv.
323,80 ^SEK	-1,64%		-0,74%	+4,05%

08/05	La FDA prolonge le délai d'examen du traitement contre Alzheimer co-développé par BioArctic	MT
08/05	Les contrats à terme signalent une ouverture en baisse pour la Bourse de Stockholm (actualisé)	FW

Communiqués

08/05	Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.	AQ
29/04	Leqembi® annual sales exceed EUR 500 million - second sales milestone achieved	AQ
29/04	Sales of Leqembi® totaled 26.2 billion yen in the first quarter 2026	AQ
21/04	Notice of Annual General Meeting 2026 in BioArctic AB (publ)	AQ
21/04	BioArctic publishes the Annual Report and Sustainability Report for 2025	AQ
27/03	The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB	AQ
23/03	BioArctic : New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress	PU
23/03	BioArctic : New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress	PU
11/03	Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress	AQ
27/02	Number of shares and votes in BioArctic AB (publ) as of February 27, 2026	AQ
24/02	BioArctic (Q4 review): High quality, high expectations	AQ
18/02	Interim Report for the period October - December 2025	AQ
13/02	BioArctic – Consensus estimates Q4 2025	AQ
11/02	BioArctic : Invitation to presentation of BioArctic’s fourth quarter report for October – December 2025 on February 18 at 9.30 a.m. CET	PU
11/02	Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET	AQ
09/02	BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China	AQ
06/02	Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025	AQ
26/01	Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)	AQ
26/01	Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA	AQ
06/01	BLA for subcutaneous formulation of Leqembi® accepted in China	AQ
09/12	Leqembi included in China's commercial insurance innovative drug list	AQ
04/12	New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment	AQ
28/11	Number of shares and votes in BioArctic AB (publ) as of November 28, 2025	AQ
28/11	New drug application for subcutaneous formulation of Leqembi[®] submitted in Japan	AQ
25/11	Eisai completes U.S. rolling sBLA submission for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose	AQ